Skip to main content
Clinical Trials/NCT07466537
NCT07466537
Not yet recruiting
Not Applicable

Efficacy and Safety of 6 Intravaginal EMS Treatments in Women With Exclusive or Predominant Stress Urinary Incontinence

IRCCS San Raffaele0 sites15 target enrollmentStarted: March 30, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
15
Primary Endpoint
Variation in patient bladder voiding diaries' results at follow up visits versus baseline

Overview

Brief Summary

The investigator wants to evaluate the efficacy of a specific intravaginal Electrical Muscle Stimulation (EMS), in the treatment of exclusive or predominant stress urinary incontinence (SUI) symptoms in women. The investigator's aim is to determine the device's impact (the device is VTone) on reducing urinary incontinence episodes and on improving women's quality of life.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women with minimum age of 18 years .
  • Documented clinical diagnosis of exclusive or predominant stress urinary incontinence.
  • Willingness to comply with study procedures and follow-up visits.
  • Signed informed consent to participate in the study.
  • BMI \</= 30.

Exclusion Criteria

  • Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.
  • Any permanent implant or an injected chemical substance in the treatment area.
  • Superficial areas that have been injected with hyaluronic acid (HA)/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
  • Current or history of cancer, or current condition of any other type of cancer, or premalignant moles.
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy
  • Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive medications.
  • Patients with a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
  • Any active condition in the treatment area, such as sores, eczema, and rash.

Arms & Interventions

Women with stress urinary incontinence treated with intravaginal electrical muscle stimulation

Experimental

We will include women suffering from stress urinary incontinence who will be treated with intravaginal electrical muscle stimulation with a device called VTone. VTone is a small anatomically shaped applicator that delivers intravaginal electrical muscle stimulation This device includes an ogival, circular body, with a handle at one end of the body and a head at the other end of the body. The head includes a substantially flat, metallic surface. The device should be used with gel. The treatment will include 6 sessions (sessions will be planned once a week) and women will be asked to fill in a bladder voiding diary and validated questionnnaires at baseline and at follow up visits (one and three months after the last treatment).

Intervention: Electrical intravaginal muscle stimulation (Device)

Outcomes

Primary Outcomes

Variation in patient bladder voiding diaries' results at follow up visits versus baseline

Time Frame: Follow up visits: 1 month and 3 months after the last session of treatment

Eligible subjects will receive a total of 8 treatments (once a week) using the transvaginal electrical stimulation. All subjects will be required to return to the clinic at 1 month and 3 months after the last treatment. At baseline and during the two follow up visits patients will be asked to fill in a bladder voiding diary.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Stefano Salvatore

Professor

IRCCS San Raffaele

Similar Trials